The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the ...
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell ...
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to ...
Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded ...
CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX ...
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a ...
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results